Table 1: Dataset statistics and input/output dimensions used in experiments	Num.	Samp.	Target	Static Temp. dim. Temp. dim.			Window Window		Effective Effective	Dataset	patients	freq.	type	dim.	(history)	(forecast)	(history) (forecast)		|X|	|Y|UKCF	10,000	1 yr.	Binary	11	43	34	3	4	140	136ADNI	1,700	6 m.	Continuous	11	26	24	4	8	115	192MIMIC	22,000	4 hr.	Mixed	26	361	361	5	5	1,831	1,805The effective input dimension |X | is computed as the dimension of static data plus the product of the width ofthe historical window (of temporal information) with its dimension; the effective target dimension |Y | is sim-ilarly computed as the product of the width of the forecast window (of temporal information) with its dimension.
Table 2: Summary results for Tea and comparators on linear model with UKCF (Bold indicates best)	Base	Reg	Fea	Tea	F/TEA	 Prc(i)	0.322 ± 0.099*	0.347 ± 0.085*	0.351 ± 0.079*	0.450 ± 0.035	0.414 ± 0.028*Prc(c)	0.416 ± 0.100*	0.433 ± 0.083*	0.455 ± 0.087*	0.559 ± 0.060	0.520 ± 0.052Roc(i)	0.689 ± 0.089*	0.710 ± 0.072*	0.720 ± 0.073	0.767 ± 0.026	0.766 ± 0.023Roc(c)	0.679 ± 0.091*	0.700 ± 0.075*	0.713 ± 0.075	0.767 ± 0.042	0.755 ± 0.037The two-sample t-test for difference in means is conducted on the results. An asterisk indicates statisticallysignificant difference in means (p-value < 0.05) relative to the TEA result. PRC and ROC metrics are reportedseparately for variables representing infections (I) and comorbidities (C). See Tables 9-10 for extended results.
Table 3: Summary results for Tea and comparators on nonlinear (Rnn) model (Bold indicates best)UKCF (Binary Targets) ∣ ADNI (Continuous Targets) ∣ MIMIC (Mixed Targets)	Prc(i)	PRC(C)	Mse(b)	Mse(c)	Prc	Mse	 Base	0.411 ±0.035*	0.497 ±0.057*	0.105 ±0.018*	0.361 ±0.064	0.142 ±0.028*	0.153 ±0.011Reg	0.415 ±0.030*	0.518 ±0.052*	0.096±0.014*	0.360 ±0.066	0.143 ±0.019*	0.152±0.010Fea	0.410 ±0.033*	0.521 ±0.054*	0.092±0.012*	0.356 ±0.068	0.144 ±0.030*	0.152±0.012Tea	0.483 ±0.045	0.583 ±0.072	0.063 ±0.010	0.330 ±0.066	0.239 ±0.039	0.150±0.012F/Tea	0.457 ±0.037	0.576 ±0.071	0.073±0.010*	0.338 ±0.067	0.166 ±0.023*	0.154±0.011The two-sample t-test for difference in means is conducted on the results. An asterisk indicates statisticallysignificant difference in means (p-value < 0.05) relative to the TEA result. For UKCF, only PRC metrics forinfections (I) and comorbidities (C) are shown due to space limitation; for ADNI, Mse metrics are reportedseparately for targets representing biomarkers (B) and cognitive tests (C). See Tables 13-14, 17-18, and 21-22.
Table 4: Summary source of gain and Tea variants on linear model with UKCF (Bold indicates best)I Neither No Joint No Staged ∣	TEA	TEA(L)	TEA(LP)PRC(I)	0.347	± 0.085	0.402 ± 0.026	0.431 ± 0.031	0.450	± 0.035	0.435	± 0.031	0.454 ± 0.036PRC(C)	0.433	± 0.083	0.507 ± 0.040	0.543 ± 0.054	0.559	± 0.060	0.544	± 0.053	0.560 ± 0.061ROC(I)	0.710	± 0.072	0.747 ± 0.022	0.764 ± 0.022	0.767	± 0.026	0.759	± 0.025	0.768 ± 0.028ROC(C)	0.700	± 0.075	0.744 ± 0.038	0.766 ± 0.038	0.767	± 0.042	0.760	± 0.042	0.767 ± 0.042“No Joint” omits final joint training, and “No Staged” skips (pre)-training stages. Prc and Roc metrics are repo-rted separately for targets representing infections (I) & comorbidities (C). See Tables 11-12 for extended results.
Table 5: Summary source of gain and Tea variants on nonlinear (Rnn) model (Bold indicates best)I UKCF (Binary Targets)			ADNI (Continuous Targets)		MIMIC (Mixed Targets)		Prc(i)	Prc(c)	Mse(B)	Mse(C)	Prc	Mse	 Neither	0.415 ±0.030	0.518±0.052	0.096 ±0.014	0.360 ±0.066	0.143±0.019	0.152±0.010No Joint	0.455±0.039	0.574 ±0.069	0.092 ±0.014	0.353 ±0.070	0.183±0.038	0.151±0.011No Staged	0.424±0.031	0.543±0.061	0.106 ±0.022	0.363 ±0.067	0.167±0.022	0.150±0.012Tea	0.483±0.045	0.583±0.072	0.063 ±0.010	0.330 ±0.066	0.239±0.039	0.150±0.012Tea(l)	0.483±0.047	0.581 ±0.074	0.058 ±0.012	0.330 ±0.076	0.249 ± 0.049	0.149 ±0.012Tea(lp)	0.480±0.044	0.583±0.072	0.064 ±0.012	0.329 ±0.068	0.229±0.039	0.151±0.011“No Joint” omits final joint training, and “No Staged” skips (pre)-training stages. For UKCF, only Prc metricsfor infections (I) and comorbidities (C) are shown due to space limitation; for ADNI, Mse metrics are reportedseparately for targets representing biomarkers (B) and cognitive tests (C). See Tables 15-16, 19-20, and 23-24.
Table 6: Autoencoder-Based Supervised Representation LearningWork	Contribution	Setting	Type	EmbeddingWeston et al. (2012)	Jointly optimized classific-	Semi-supervised	Deterministic	Features	ation and embedding	learning		Kingma et al. (2014)	Variational inference for generative modeling	Semi-supervised learning	Probabilistic	FeaturesNarayanaswamy et al.	Disentangled latent	Semi-supervised	Probabilistic	Features(2017)	representations	learning		Zhuang et al. (2015)	Input- and output-encoding for transfer learning	Semi-supervised learning	Deterministic	FeaturesBousmalis et al. (2016)	Paired autoencoders for	Semi-supervised	Deterministic	Features	transfer learning	learning		Ghifary et al. (2016)	Jointly optimized feature-embedding	Semi-supervised learning	Deterministic	FeaturesLe et al. (2018)	Jointly optimized	Supervised	Deterministic	Features	feature-embedding	learning		Dalca et al. (2018)	Generative model using learned target priors	Unsupervised, Unpaired	Probabilistic	TargetsGirdhar et al. (2016)	Jointly optimized target- embedding (Indirect)	Supervised learning	Deterministic	Targets(Ours)	Jointly optimized target- embedding (Direct)	Supervised learning	Deterministic	TargetsAutoencoder-based representation learning (Hinton & Salakhutdinov, 2006) has long played impor-tant roles in unsupervised and semi-supervised settings. Various inductive biases have been proposedto promote representations that are sparse (Ranzato et al., 2007), discrete (van den Oord et al., 2017),factorized (Chen et al., 2018), or hierarchical (Zhao et al., 2017), among others. For a more thorough
Table 7: Label Space Dimension Reduction via Label EmbeddingWork	Contribution	Learning	ProblemHsu et al. (2009)	Coding with compressed sensing (random projections)	Separate	Multi-label classificationTai & Lin (2010)	Coding with principal label space transformation (PC-based projections)	Separate	Multi-label classificationZhang & Schneider	Coding with maximum margin (between	Separate	Multi-label(2011)	prediction distances)		classificationBalasubramanian &	Landmark selection of labels via	Separate	Multi-labelLebanon (2012)	group-sparse learning		classificationBi & Kwok (2013)	Landmark selection of labels via	Separate	Multi-label	randomized sampling		classificationChen & Lin (2012)	Feature-aware principal label space transformation for embedding	Joint	Multi-label classificationYu et al. (2014)	Generic empirical risk minimization	Joint	Multi-label	formulation and bounds		classificationYeh et al. (2017)	Autoencoder embedding with	Joint	Multi-label	canonical correlation analysis		classificationMostajabi et al. (2018)	Autoencoder component as (Implicit) regularization for learning predictor	Separate	General; Semantic segmentation(Ours)	Autoencoder component as (Explicit)	Joint	General; Sequence	regularization for learning predictor		forecastingOktay et al. (2017) deploy a similar approach for medical image segmentation. On the other hand,in both cases the supervised task is truncated: the predictors are trained to regress the unsupervised
Table 8: Generalizability, Multiple Tasks, and Algorithmic StabilityWork	Contribution	Setting	Focus	LearningBousquet & Elisseeff (2002)	Uniform stability for generalization	Supervised, general	Single task	-Feldman & Vondrak (2018)	Improve on Bousquet & Elisseefrs bound	Supervised, general	Single task	-Baxter (2000)	VC-dimension for	Multi-task	All tasks	Jointly	generalization	learning		Maurer (2006)	RademaCher complexity for generalization	Multi-task learning	All tasks	JointlyLiu et al. (2016)	Uniform stability for generalization	Multi-task learning	All tasks	JointlyMohri et al. (2015)	Rademacher complexity for generalization	Feature- embedding	Primary task	Separately	Non-contractiveness and	Feature-	Primary task	SeparatelyEpstein & Meir (2019)	semi-supervision	embedding		Le et al. (2018)	Uniform stability for generalization	Feature- embedding	Primary task	Jointly(Ours)	Uniform stability for generalization	Target- embedding	Primary task	Jointlyaddition of specific losses to exploit correlations—a tactic also used in Wang et al. (2018) withmulti-dimensional scaling. Furthermore, nonlinearities can be handled by deep learning in componentfunctions, unlike earlier approaches limited to kernel methods (Lin et al., 2014; Li & Guo, 2015).
Table 9: Extended results for Tea and comparators on linear model with UKCF (Bold indicates best)	T	Base	REG	FEA	Tea	F/TEA	 Prc(i)	1	0.340 ± 0.118*	0.370 ± 0.101*	0.374 ± 0.091*	0.497 ± 0.016	0.454 ± 0.010*	2	0.325 ± 0.099*	0.350 ±0.085*	0.353 ± 0.077*	0.459 ± 0.017	0.419 ± 0.012*	3	0.314 ± 0.088*	0.337 ± 0.076*	0.342 ± 0.071*	0.432 ± 0.015	0.399 ± 0.013*	4	0.307 ± 0.082*	0.328 ± 0.071*	0.333 ± 0.067*	0.413 ± 0.010	0.386 ± 0.009*Prc(c)	1	0.445 ± 0.131*	0.467 ± 0.106*	0.499 ± 0.110*	0.653 ± 0.009	0.599 ± 0.019*	2	0.418 ± 0.099*	0.435 ± 0.081*	0.457 ± 0.083*	0.566 ± 0.010	0.524 ± 0.017*	3	0.403 ± 0.082*	0.418 ± 0.067*	0.436 ± 0.069*	0.521 ± 0.008	0.487 ± 0.015*	4	0.398 ± 0.073*	0.412 ± 0.060*	0.426 ± 0.061*	0.498 ± 0.009	0.471 ± 0.013*Roc(i)	1	0.713 ± 0.104*	0.737 ± 0.081*	0.750 ± 0.078	0.806 ± 0.007	0.801 ± 0.007	2	0.688 ± 0.089*	0.709 ± 0.070*	0.718 ± 0.068*	0.771 ± 0.007	0.765 ± 0.009	3	0.677 ± 0.080*	0.697 ±0.065*	0.706 ± 0.066	0.750 ± 0.007	0.749 ± 0.009	4	0.677 ± 0.076*	0.696 ± 0.063	0.707 ± 0.068	0.740 ± 0.008	0.748 ± 0.006*Roc(c)	1	0.713 ± 0.110*	0.741 ± 0.088*	0.756 ± 0.084*	0.829 ± 0.006	0.810 ± 0.008*	2	0.686 ± 0.091*	0.707 ± 0.072*	0.719 ± 0.071*	0.775 ± 0.008	0.762 ± 0.008*	3	0.668 ± 0.077*	0.686 ± 0.061*	0.699 ± 0.063	0.743 ± 0.005	0.735 ± 0.007*	4	0.651 ± 0.070*	0.667 ± 0.056*	0.679 ± 0.057*	0.720 ± 0.006	0.712 ± 0.009*Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 10: Summary results for Tea and comparators on linear model with UKCF (Bold indicates best)	I	Base	I	Reg	FEA	Tea	F/TEAPrc(i)	I 0.322 ± 0.099*	I 0.347 ± 0.085*	0.351 ± 0.079*	0.450 ± 0.035	0.414 ± 0.028*Prc(c)	I 0.416 ± 0.100*	I 0.433 ± 0.083*	0.455 ± 0.087*	0.559 ± 0.060	0.520 ± 0.052Roc(i)	I 0.689 ± 0.089*	I 0.710 ± 0.072*	0.720 ± 0.073	0.767 ± 0.026	0.766 ± 0.023Roc(c)	I 0.679 ± 0.091*	I 0.700 ± 0.075*	0.713 ± 0.075	0.767 ± 0.042	0.755 ± 0.037Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 11: Extended source of gain and variants on linear model with UKCF (Bold indicates best)	T	No Joint	No Staged	Tea	Tea(l)	Tea(lp)	 Prc(i)	1	0.434 ± 0.017	0.472 ± 0.016	0.497 ± 0.016	0.474 ± 0.018	0.502 ± 0.015	2	0.408 ± 0.016	0.439 ± 0.016	0.459 ± 0.017	0.443 ± 0.018	0.463 ± 0.016	3	0.390 ± 0.015	0.415 ± 0.015	0.432 ± 0.015	0.420 ± 0.014	0.435 ± 0.013	4	0.377 ± 0.014	0.399 ± 0.011	0.413 ± 0.010	0.402 ± 0.010	0.415 ± 0.009Prc(c)	1	0.563 ± 0.025	0.620 ± 0.030	0.653 ± 0.009	0.626 ± 0.012	0.655 ± 0.008	2	0.511 ± 0.018	0.550 ± 0.022	0.566 ± 0.010	0.550 ± 0.008	0.566 ± 0.010	3	0.484 ± 0.014	0.512 ±0.017	0.521 ± 0.008	0.511 ± 0.006	0.521 ± 0.008	4	0.469 ± 0.014	0.491 ± 0.015	0.498 ± 0.009	0.490 ± 0.009	0.499 ± 0.009Roc(i)	丁	0.779 ± 0.008	0.799 ± 0.007	0.806 ± 0.007	0.797 ± 0.007	0.809 ± 0.005	2	0.750 ± 0.008	0.765 ± 0.009	0.771 ± 0.007	0.763 ± 0.008	0.772 ± 0.00725Published as a conference paper at ICLR 2020	3	0.733 ± 0.008	0.750 ± 0.008	0.750 ± 0.007	0.744 ± 0.007	0.750 ± 0.008	4	0.725 ± 0.007	0.744 ± 0.005	0.740 ± 0.008	0.734 ± 0.006	0.740 ± 0.007	 Roc(c)	1	0.799 ± 0.012	0.821 ± 0.011	0.829 ± 0.006	0.823 ± 0.005	0.830 ± 0.005	2	0.751 ± 0.012	0.774 ± 0.009	0.775 ± 0.008	0.769 ± 0.006	0.775 ± 0.006	3	0.723 ± 0.010	0.746 ± 0.007	0.743 ± 0.005	0.737 ± 0.005	0.742 ± 0.005	4	0.702 ± 0.011	0.722 ± 0.007	0.720 ± 0.006	0.713±0.008	0.720 ± 0.006
Table 12: Summary source of gain and variants on linear model with UKCF (Bold indicates best)	I	No Joint	No Staged	I	Tea	Tea(l)	Tea(lp)Prc(i)	I 0.402 ± 0.026	0.431 ± 0.031	I 0.450 ± 0.035	0.435 ± 0.031	0.454 ± 0.036Prc(c)	I 0.507 ± 0.040	0.543 ± 0.054	I 0.559 ± 0.060	0.544 ± 0.053	0.560 ± 0.061Roc(i)	I 0.747 ± 0.022	0.764 ± 0.022	I 0.767 ± 0.026	0.759 ± 0.025	0.768 ± 0.028Roc(c)	I 0.744 ± 0.038	0.766 ± 0.038	I 0.767 ± 0.042	0.760 ± 0.042	0.767 ± 0.042Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 13: Extended results for Tea and comparators on Rnn model with UKCF (Bold indicates best)	T	Base	REG	FEA	Tea	F/TEA	 Prc(i)	1	0.451 ± 0.027*	0.456 ± 0.016*	0.448 ± 0.026*	0.549 ± 0.014	0.509 ± 0.014*	2	0.417 ± 0.024*	0.420 ±0.013*	0.416 ± 0.022*	0.490 ± 0.012	0.463 ± 0.011*	3	0.395 ± 0.019*	0.400 ±0.013*	0.395 ± 0.020*	0.457 ± 0.010	0.437 ± 0.013*	4	0.380 ± 0.017*	0.385 ± 0.010*	0.380 ± 0.017*	0.434 ± 0.007	0.417 ± 0.013*Prc(c)	1	0.561 ± 0.056*	0.592 ± 0.029*	0.598 ± 0.029*	0.695 ± 0.010	0.685 ± 0.015	2	0.504 ± 0.039*	0.523 ± 0.022*	0.527 ± 0.021*	0.591 ± 0.014	0.584 ± 0.018	3	0.471 ± 0.028*	0.488 ± 0.018*	0.489 ± 0.017*	0.537 ± 0.007	0.530 ± 0.017	4	0.453 ± 0.023*	0.469 ± 0.017*	0.470 ± 0.016*	0.510 ± 0.007	0.504 ± 0.015Roc(i)	1	0.788 ± 0.018*	0.791 ± 0.009*	0.794 ± 0.014*	0.827 ± 0.007	0.818 ± 0.006*	2	0.753 ± 0.015*	0.757 ± 0.011*	0.758 ± 0.017*	0.783 ± 0.008	0.778 ± 0.009	3	0.736 ± 0.013*	0.741 ± 0.012*	0.740 ± 0.016*	0.760 ± 0.007	0.757 ± 0.010	4	0.725 ± 0.012*	0.731 ± 0.011*	0.727 ± 0.014*	0.748 ± 0.008	0.744 ± 0.010Roc(c)	1	0.794 ± 0.022*	0.809 ±0.015*	0.808 ± 0.012*	0.838 ± 0.007	0.834 ± 0.007	2	0.750 ± 0.017*	0.761 ± 0.010*	0.761 ± 0.009*	0.782 ± 0.007	0.781 ± 0.008	3	0.723 ± 0.013*	0.733 ± 0.007*	0.735 ± 0.010*	0.752 ± 0.006	0.751 ± 0.009	4	0.699 ± 0.009*	0.709 ± 0.009*	0.711 ± 0.010*	0.726 ± 0.006	0.724 ± 0.008Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 14: Summary results for Tea and comparators on Rnn model with UKCF (Bold indicates best)	I	Base	I	Reg	FEA	Tea	F/TEAPrc(i)	I 0.411 ±0.035*	I 0.415 ± 0.030*	0.410 ± 0.033*	0.483 ± 0.045	0.457 ± 0.037Prc(c)	I 0.497 ± 0.057*	I 0.518 ± 0.052*	0.521 ± 0.054*	0.583 ± 0.072	0.576 ± 0.071Roc(i)	I 0.750 ± 0.028*	I 0.755 ± 0.025	0.755 ± 0.029	0.779 ± 0.031	0.774 ± 0.030Roc(c)	I 0.742 ± 0.038	I 0.753 ± 0.039	0.754 ± 0.037	0.774 ± 0.042	0.772 ± 0.04226Published as a conference paper at ICLR 2020Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 15: Extended source of gain and variants on Rnn model with UKCF (Bold indicates best)	T	No Joint	No Staged	Tea	Tea(l)	Tea(lp)	 Prc(i)	1	0.511 ± 0.014	0.468 ± 0.015	0.549 ± 0.014	0.553 ± 0.009	0.545 ± 0.011	2	0.461 ± 0.013	0.429 ± 0.011	0.490 ± 0.012	0.492 ± 0.013	0.487 ± 0.012	3	0.434 ± 0.016	0.407 ± 0.011	0.457 ± 0.010	0.457 ± 0.013	0.455 ± 0.014	4	0.414 ± 0.009	0.392 ± 0.011	0.434 ± 0.007	0.432 ± 0.008	0.433 ± 0.009Prc(c)	1	0.682 ± 0.011	0.633 ± 0.032	0.695 ± 0.010	0.697 ± 0.010	0.695 ± 0.012	2	0.581 ± 0.012	0.549 ± 0.025	0.591 ± 0.014	0.589 ± 0.013	0.592 ± 0.011	3	0.530 ± 0.010	0.506 ± 0.018	0.537 ± 0.007	0.534 ± 0.009	0.538 ± 0.009	4	0.504 ± 0.009	0.484 ± 0.015	0.510 ± 0.007	0.505 ± 0.008	0.509 ± 0.010Roc(i)	1	0.816 ± 0.004	0.795 ± 0.008	0.827 ± 0.007	0.825 ± 0.005	0.822 ± 0.010	2	0.774 ± 0.010	0.759 ± 0.007	0.783 ± 0.008	0.782 ± 0.008	0.778 ± 0.007	3	0.749 ± 0.010	0.744 ± 0.008	0.760 ± 0.007	0.758 ± 0.006	0.758 ± 0.006	4	0.732 ± 0.008	0.735 ± 0.008	0.748 ± 0.008	0.739 ± 0.007	0.745 ± 0.004Roc(c)	1	0.830 ± 0.008	0.816 ± 0.011	0.838 ± 0.007	0.839 ± 0.008	0.839 ± 0.007	2	0.775 ± 0.010	0.767 ± 0.009	0.782 ± 0.007	0.784 ± 0.010	0.782 ± 0.005	3	0.743 ± 0.009	0.735 ± 0.007	0.752 ± 0.006	0.751 ± 0.010	0.751 ± 0.007	4	0.721 ± 0.006	0.712 ± 0.007	0.726 ± 0.006	0.724±0.007	0.726 ± 0.006Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 16: Summary source of gain and variants on Rnn model with UKCF (Bold indicates best)	I	No Joint	No Staged	I	Tea	Tea(l)	Tea(lp)Prc(i)	I 0.455 ± 0.039	0.424 ± 0.031	I 0.483 ± 0.045	0.483 ± 0.047	0.480 ± 0.044Prc(c)	I 0.574 ± 0.069	0.543 ± 0.061	I 0.583 ± 0.072	0.581 ± 0.074	0.583 ± 0.072Roc(i)	I 0.768 ± 0.033	0.758 ± 0.024	I 0.779 ± 0.031	0.776 ± 0.033	0.776 ± 0.030Roc(c)	I 0.767 ± 0.042	0.758 ± 0.040	I 0.774 ± 0.042	0.774 ± 0.044	0.774 ± 0.043Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 17: Extended results for Tea and comparators on Rnn model with ADNI (Bold indicates best)	T	Base	REG	FEA	Tea	F/TEA	 Mse(b)	1	0.095 ± 0.014*	0.088 ± 0.010*	0.082 ± 0.007*	0.057 ± 0.007	0.065 ± 0.008*	2	0.097 ± 0.015*	0.089 ± 0.010*	0.084 ± 0.008*	0.057 ± 0.007	0.066 ± 0.007*	3	0.100 ± 0.015*	0.092 ± 0.010*	0.087 ± 0.008*	0.059 ± 0.007	0.068 ± 0.007*	4	0.104 ± 0.016*	0.095 ± 0.011*	0.091 ± 0.008*	0.061 ± 0.007	0.071 ± 0.008*	5	0.105 ± 0.017*	0.097 ± 0.012*	0.093 ± 0.008*	0.062 ± 0.008	0.073 ± 0.008*	6	0.109 ± 0.017*	0.100 ± 0.013*	0.097 ± 0.009*	0.065 ± 0.008	0.076 ± 0.009*	7	0.112 ± 0.019*	0.103 ± 0.014*	0.101 ± 0.011*	0.068 ± 0.009	0.080 ± 0.009*	8	0.115 ± 0.021*	0.106 ± 0.016*	0.105 ± 0.013*	0.072 ± 0.011	0.083 ± 0.010*Mse(c)	1	0.275 ± 0.013*	0.270 ± 0.013*	0.265 ± 0.011*	0.239 ± 0.015	0.243 ± 0.013	2	0.300 ± 0.015*	0.295 ± 0.013*	0.290 ± 0.012*	0.265 ± 0.014	0.273 ± 0.014	3	0.323 ± 0.018*	0.320 ± 0.015*	0.314 ±0.013*	0.287 ± 0.014	0.297 ± 0.015	4	0.358 ± 0.019*	0.354 ± 0.018*	0.352 ± 0.017*	0.322 ± 0.015	0.333 ± 0.018	5	0.371 ± 0.024*	0.370 ± 0.023*	0.367 ± 0.023*	0.341 ± 0.019	0.350 ± 0.021	6	0.393 ± 0.033	0.393 ± 0.032	0.391 ± 0.034	0.366 ± 0.026	0.374 ± 0.028	7	0.417 ± 0.043	0.419 ± 0.040	0.417 ± 0.044	0.394 ± 0.035	0.399 ± 0.03827Published as a conference paper at ICLR 2020I 8 I 0.453 ± 0.058 I 0.455 ± 0.054	0.454 ± 0.062	0.430 ± 0.048	0.435 ± 0.057
Table 18: Summary results for Tea and comparators on Rnn model with ADNI (Bold indicates best)	I	Base	I	REG	FEA	Tea	F/TEAMse(b)	I 0.105 ± 0.018*	I 0.096 ± 0.014*	0.092 ± 0.012*	0.063 ± 0.010	0.073 ± 0.010*Mse(c)	I 0.361 ± 0.064	I 0.360 ± 0.066	0.356 ± 0.068	0.330 ± 0.066	0.338 ± 0.067Mse evaluations reported separately for targets representing quantitative biomarkers (B) and cognitive tests (C).
Table 19: Extended source of gain and variants on Rnn model with ADNI (Bold indicates best)	T	No Joint	No Staged	Tea	Tea(l)	Tea(lp)	 Mse(b)	1	0.081 ± 0.011	0.098 ± 0.018	0.057 ± 0.007	0.049 ± 0.009	0.057 ± 0.009	2	0.084 ± 0.011	0.098 ± 0.018	0.057 ± 0.007	0.051 ± 0.010	0.058 ± 0.008	3	0.087 ± 0.011	0.101 ± 0.019	0.059 ± 0.007	0.054 ± 0.011	0.059 ± 0.008	4	0.090 ± 0.011	0.105 ± 0.019	0.061 ± 0.007	0.056 ± 0.011	0.062 ± 0.008	5	0.092 ± 0.011	0.106 ± 0.021	0.062 ± 0.008	0.059 ± 0.011	0.064 ± 0.009	6	0.097 ± 0.012	0.110 ± 0.023	0.065 ± 0.008	0.063 ± 0.011	0.068 ± 0.010	7	0.100 ± 0.013	0.113 ± 0.025	0.068 ± 0.009	0.066 ± 0.010	0.072 ± 0.011	8	0.104 ± 0.014	0.117 ± 0.027	0.072 ± 0.011	0.070 ± 0.011	0.076 ± 0.013Mse(c)	1	0.258 ± 0.016	0.274 ± 0.017	0.239 ± 0.015	0.231 ± 0.020	0.241 ± 0.016	2	0.285 ± 0.016	0.297 ± 0.017	0.265 ± 0.014	0.258 ± 0.021	0.266 ± 0.018	3	0.311 ± 0.017	0.321 ± 0.018	0.287 ± 0.014	0.282 ± 0.021	0.287 ± 0.018	4	0.346 ± 0.019	0.356 ± 0.020	0.322 ± 0.015	0.319 ± 0.021	0.321 ± 0.022	5	0.363 ± 0.024	0.373 ± 0.024	0.341 ± 0.019	0.337 ± 0.024	0.338 ± 0.026	6	0.389 ± 0.033	0.397 ± 0.031	0.366 ± 0.026	0.366 ± 0.030	0.362 ± 0.033	7	0.416 ± 0.041	0.424 ± 0.040	0.394 ± 0.035	0.401 ± 0.043	0.390 ± 0.044	8	0.454 ± 0.059	0.462 ± 0.053	0.430 ± 0.048	0.447 ± 0.064	0.427 ± 0.063Mse evaluations reported separately for targets representing quantitative biomarkers (B) and cognitive tests (C).
Table 20: Summary source of gain and variants on Rnn model with ADNI (Bold indicates best)	I No Joint	No Staged	I	Tea	Tea(l)	Tea(lp)Mse(b)	I 0.092 ± 0.014	0.106±0.022	I 0.063 ± 0.010	0.058 ± 0.012	0.064 ±0.012Mse(c)	I 0.353 ± 0.070	0.363 ± 0.067	I 0.330 ± 0.066	0.330 ± 0.076	0.329 ± 0.068Mse evaluations reported separately for targets representing quantitative biomarkers (B) and cognitive tests (C).
Table 21: Extended results for Tea and comparators on Rnn model with MIMIC (Bold indicates best)	T	Base	Reg	FEA	Tea	F/TEA	 Prc	1	0.159 ± 0.034*	0.159 ± 0.022*	0.162 ± 0.036*	0.293 ± 0.031	0.193 ± 0.023*	2	0.148 ± 0.028*	0.149 ± 0.018*	0.150 ± 0.030*	0.254 ± 0.025	0.174 ± 0.018*	3	0.139 ± 0.024*	0.141 ± 0.015*	0.142 ± 0.027*	0.230 ± 0.021	0.162 ±0.015*	4	0.133 ± 0.021*	0.135 ± 0.012*	0.135 ± 0.024*	0.214 ± 0.018	0.153 ± 0.012*	5	0.129 ± 0.019*	0.130 ± 0.011*	0.130 ± 0.022*	0.203 ± 0.015	0.147 ± 0.011*Roc	丁	0.699 ± 0.049*	0.704 ± 0.028*	0.709 ± 0.060*	0.801 ± 0.018	0.745 ± 0.021*28Published as a conference paper at ICLR 2020	2	0.701 ± 0.044*	0.707 ± 0.025*	0.705 ± 0.050*	0.778 ± 0.015	0.740 ± 0.018*	3	0.690 ± 0.041*	0.696 ± 0.024*	0.693 ± 0.046*	0.758 ± 0.016	0.726 ± 0.019*	4	0.681 ± 0.038*	0.688 ± 0.023*	0.684 ± 0.042*	0.745 ± 0.015	0.715 ± 0.019*	5	0.679 ± 0.037*	0.685 ± 0.023*	0.680 ± 0.043*	0.736 ± 0.012	0.713 ± 0.019*Mse	1	0.141 ± 0.007	0.140 ± 0.006	0.138 ± 0.010	0.137 ± 0.008	0.139 ± 0.007	2	0.159 ± 0.010	0.159 ± 0.007	0.160 ± 0.008	0.154 ± 0.009	0.162 ±0.007*	3	0.156 ± 0.009	0.155 ± 0.007	0.156 ± 0.008	0.158 ± 0.008	0.158 ± 0.008	4	0.154 ± 0.008	0.153 ± 0.008	0.153 ± 0.008	0.153 ± 0.009	0.155 ± 0.009	5	0.154 ± 0.010	0.152 ± 0.010	0.152 ± 0.010	0.150 ± 0.011	0.155 ± 0.010The two-sample t-test for a difference in means is conducted on the results. An asterisk next to the comparator
Table 22: Summary results for Tea and comparators on Rnn model with MIMIC (Bold indicates best)	I	Base	I	REG	FEA	Tea	F/TEAPrc	I 0.142 ± 0.028*	I 0.143 ± 0.019*	0.144 ± 0.030*	0.239 ± 0.039	0.166 ±0.023*Roc	I 0.690 ± 0.043*	I 0.696 ± 0.026*	0.694 ± 0.050*	0.763 ± 0.028	0.728 ± 0.023*Mse	I 0.153 ± 0.011	I 0.152 ± 0.010	0.152 ± 0.012	0.150 ± 0.012	0.154 ± 0.011The two-sample t-test for a difference in means is conducted on the results. An asterisk next to the comparatorresult is used to indicate a statistically significant difference in means (p-value < 0.05) relative to the TEA result.
Table 23: Extended source of gain and variants on Rnn model with MIMIC (Bold indicates best)	T	No Joint	No Staged	Tea	Tea(l)	Tea(lp)	 Prc	1	0.216 ± 0.044	0.194 ± 0.020	0.293 ± 0.031	0.310 ± 0.047	0.280 ± 0.033	2	0.194 ± 0.035	0.175 ± 0.017	0.254 ± 0.025	0.265 ± 0.035	0.242 ± 0.026	3	0.178 ± 0.030	0.163 ± 0.013	0.230 ± 0.021	0.239 ± 0.030	0.221 ± 0.022	4	0.168 ± 0.027	0.154 ± 0.011	0.214 ± 0.018	0.222 ± 0.026	0.206 ± 0.020	5	0.160 ± 0.024	0.148 ± 0.010	0.203 ± 0.015	0.210 ± 0.023	0.195 ± 0.018Roc	1	0.756 ± 0.042	0.742 ± 0.022	0.801 ± 0.018	0.807 ± 0.025	0.791 ± 0.018	2	0.741 ± 0.031	0.738 ± 0.021	0.778 ± 0.015	0.783 ± 0.017	0.773 ± 0.012	3	0.726 ± 0.031	0.724 ± 0.019	0.758 ± 0.016	0.761 ± 0.019	0.756 ± 0.013	4	0.715 ± 0.030	0.715 ± 0.019	0.745 ± 0.015	0.747 ± 0.017	0.742 ± 0.011	5	0.710 ± 0.031	0.711 ± 0.018	0.736 ± 0.012	0.741 ± 0.019	0.736 ± 0.014Mse	1	0.138 ± 0.008	0.137 ± 0.007	0.137 ± 0.008	0.136 ± 0.006	0.137 ± 0.008	2	0.158 ± 0.007	0.156 ± 0.012	0.154 ± 0.009	0.153 ± 0.007	0.154 ± 0.007	3	0.155 ± 0.009	0.156 ± 0.010	0.158 ± 0.008	0.156 ± 0.010	0.158 ± 0.008	4	0.152 ± 0.008	0.153 ± 0.009	0.153 ± 0.009	0.151 ± 0.011	0.154 ± 0.008	5	0.151 ± 0.009	0.150 ± 0.009	0.150 ± 0.011	0.147 ± 0.011	0.150 ± 0.008The "No Joint" setting isolates the benefit from staged training only (analogous to basic unsupervised pretraining,though using targets); the "No Staged" setting isolates the benefit from joint training only (without pretraining).
Table 24: Summary source of gain and variants on Rnn model with MIMIC (Bold indicates best)	I	No Joint	No Staged	I	Tea	Tea(l)	Tea(lp)Prc	I 0.183 ± 0.038	0.167 ± 0.022	I 0.239 ± 0.039	0.249 ± 0.049	0.229 ± 0.039Roc	I 0.730 ± 0.038	0.726 ± 0.023	I 0.763 ± 0.028	0.768 ± 0.031	0.759 ± 0.025Mse	I 0.151 ± 0.011	0.150 ± 0.012	I 0.150 ± 0.012	0.149 ± 0.012	0.151 ± 0.011The "No Joint" setting isolates the benefit from staged training only (analogous to basic unsupervised pretraining,though using targets); the "No Staged" setting isolates the benefit from joint training only (without pretraining).
Table 25: Extended ν -Sensitivities for REG on linear model with UKCF (Bold indicates best)	T	V = 0	ν = 3e-5	v = 3e-4	ν = 3e-3	ν = 3e-2	 Prc(i)	1 2 3 4	0.340 ± 0.118 0.325 ± 0.099 0.314 ± 0.088 0.307 ± 0.082	0.355 ± 0.114 0.338 ± 0.096 0.327 ± 0.086 0.318±0.080	0.370 ± 0.101 0.350 ± 0.085 0.337 ± 0.076 0.328 ± 0.071	0.320 ± 0.034 0.309 ± 0.026 0.300 ± 0.024 0.293 ± 0.023	0.163 ± 0.003 0.176 ± 0.004 0.182 ±0.005 0.184 ± 0.004Prc(c)	1 2 3 4	0.445 ± 0.131 0.418 ± 0.099 0.403 ± 0.082 0.398 ± 0.073	0.460 ± 0.125 0.428 ± 0.095 0.412±0.078 0.406 ± 0.070	0.467 ± 0.106 0.435 ± 0.081 0.418 ± 0.067 0.412±0.060	0.426 ± 0.034 0.409 ± 0.025 0.399 ± 0.021 0.397 ± 0.019	0.240 ± 0.004 0.260 ± 0.005 0.272 ± 0.006 0.281 ± 0.007Roc(i)	1 2 3 4	0.713 ± 0.104 0.688 ± 0.089 0.677 ± 0.080 0.677 ± 0.076	0.724±0.100 0.697 ± 0.086 0.686 ± 0.078 0.686 ± 0.074	0.737 ± 0.081 0.709 ± 0.070 0.697 ± 0.065 0.696 ± 0.063	0.715 ± 0.022 0.693 ± 0.022 0.683 ± 0.021 0.681 ± 0.019	0.527 ± 0.006 0.532 ± 0.008 0.543 ± 0.007 0.555 ± 0.007Roc(c)	1 2 3 4	0.713 ± 0.110 0.686 ± 0.091 0.668 ± 0.077 0.651 ± 0.070	0.727 ± 0.105 0.696 ± 0.086 0.678 ± 0.074 0.660 ± 0.066	0.741 ± 0.088 0.707 ± 0.072 0.686 ± 0.061 0.667 ± 0.056	0.716 ± 0.025 0.686 ± 0.022 0.668 ± 0.021 0.652 ± 0.018	0.512 ±0.010 0.523 ± 0.008 0.530 ± 0.013 0.527 ± 0.015The ν coefficient controls the strength of `2 -regularization applied on top of the original loss function minimized.
Table 26: Summary ν -Sensitivities for REG on linear model with UKCF (Bold indicates best)	I	v = 0	v = 3e-5	v = 3e-4	v = 3e-3	v = 3e-2Prc(i)	I 0.322 ± 0.099	0.335 ± 0.096	0.347 ± 0.085	0.305 ± 0.029	0.176±0.009Prc(c)	I 0.416 ± 0.100	0.426 ± 0.097	0.433 ± 0.083	0.408 ± 0.028	0.263 ± 0.016Roc(i)	I 0.689 ± 0.089	0.698 ± 0.087	0.710 ± 0.072	0.693 ± 0.025	0.540 ± 0.013Roc(c)	I 0.679 ± 0.091	0.690 ± 0.087	0.700 ± 0.075	0.681 ± 0.032	0.523 ± 0.013The ν coefficient controls the strength of `2 -regularization applied on top of the original loss function minimized.
Table 27: Extended ν -Sensitivities for TEA on linear model with UKCF (Bold indicates best)	T	v = 0	v = 3e-5	v = 3e-4	v = 3e-3	v = 3e-2	 Prc(i)	1 2 3 4	0.484 ± 0.020 0.450 ± 0.016 0.424 ± 0.014 0.405 ± 0.012	0.489 ± 0.019 0.453 ± 0.016 0.426 ± 0.013 0.407 ± 0.010	0.497 ± 0.016 0.459 ± 0.017 0.432 ± 0.015 0.413±0.010	0.442 ± 0.005 0.414 ± 0.007 0.394 ± 0.009 0.381 ± 0.008	0.174 ± 0.004 0.186 ±0.005 0.192 ± 0.005 0.193 ± 0.004Prc(c)	1 2 3 4	0.641 ± 0.021 0.561 ± 0.013 0.519 ± 0.008 0.495 ± 0.008	0.644 ± 0.019 0.562 ± 0.011 0.519±0.007 0.496 ± 0.007	0.653 ± 0.009 0.566 ± 0.010 0.521 ± 0.008 0.498 ± 0.009	0.612 ±0.009 0.544 ± 0.007 0.508 ± 0.005 0.489 ± 0.007	0.276 ± 0.007 0.293 ± 0.008 0.302 ± 0.008 0.309 ± 0.009Roc(i)	1 2 3 4	0.800 ± 0.015 0.765 ± 0.009 0.746 ± 0.008 0.736 ± 0.006	0.803 ± 0.015 0.767 ± 0.011 0.747 ± 0.008 0.737 ± 0.007	0.806 ± 0.007 0.771 ± 0.007 0.750 ± 0.007 0.740 ± 0.008	0.779 ± 0.007 0.751 ± 0.007 0.735 ± 0.007 0.727 ± 0.005	0.555 ± 0.005 0.557 ± 0.007 0.565 ± 0.006 0.575 ± 0.006Roc(c)	1 2 3 4	0.825 ± 0.011 0.772 ± 0.010 0.742 ± 0.004 0.718 ± 0.006	0.826 ± 0.010 0.774±0.009 0.744 ± 0.004 0.720 ± 0.006	0.829 ± 0.006 0.775 ± 0.008 0.743 ± 0.005 0.720 ± 0.006	0.819 ± 0.006 0.771 ± 0.006 0.741 ± 0.004 0.717 ± 0.008	0.560 ± 0.011 0.564 ± 0.009 0.566 ± 0.012 0.561 ± 0.015The ν coefficient controls the strength of `2 -regularization applied on top of the original loss function minimized.
Table 28: Summary ν -Sensitivities for TEA on linear model with UKCF (Bold indicates best)	I	V = 0	ν = 3e-5	v = 3e-4	ν = 3e-3	ν = 3e-2Prc(i)	I 0.441 ± 0.033	0.444 ± 0.034	0.450 ± 0.035	0.408 ± 0.024	0.186 ±0.009Prc(c)	I 0.554 ± 0.057	0.555 ± 0.058	0.559 ± 0.060	0.538 ± 0.047	0.295 ± 0.015Roc(i)	I 0.762 ± 0.026	0.763 ± 0.028	0.767 ± 0.026	0.748 ± 0.021	0.563 ± 0.010Roc(c)	I 0.764 ± 0.041	0.766 ± 0.041	0.767 ± 0.042	0.762 ± 0.039	0.563 ± 0.012The ν coefficient controls the strength of `2 -regularization applied on top of the original loss function minimized.
Table 29: Extended λ-Sensitivities for TEA on linear model with UKCF (Bold indicates best)	T	λ = 0	λ = 0.01	λ = 0.1	λ = 0.5	λ=0.9	λ = 0.99	λ=1	 Prc(i)	1	0.370 ± 0.101	0.383 ± 0.106	0.412 ± 0.091	0.472 ± 0.016	0.461 ± 0.012	0.327 ± 0.011	0.150 ± 0.008	2	0.350 ± 0.085	0.361 ± 0.090	0.386 ± 0.076	0.439 ± 0.016	0.431 ± 0.012	0.323 ± 0.011	0.162 ± 0.008	3	0.337 ± 0.076	0.347 ± 0.081	0.368 ± 0.068	0.415 ± 0.015	0.410 ± 0.009	0.316 ±0.012	0.168 ± 0.007	4	0.328 ± 0.071	0.337 ± 0.075	0.357 ± 0.064	0.399 ± 0.011	0.395 ± 0.008	0.307 ± 0.011	0.170 ± 0.007Prc(c)	1	0.467 ± 0.106	0.481 ± 0.110	0.528 ± 0.104	0.620 ± 0.030	0.620 ± 0.016	0.433 ± 0.012	0.236 ± 0.012	2	0.435 ±0.081	0.445 ± 0.084	0.481 ± 0.079	0.550 ± 0.022	0.553 ± 0.013	0.427 ± 0.010	0.249 ± 0.010	3	0.418 ± 0.067	0.427 ± 0.070	0.456 ± 0.064	0.512 ± 0.017	0.516 ± 0.009	0.421 ± 0.009	0.259 ± 0.011	4	0.412 ± 0.060	0.420 ± 0.062	0.445 ± 0.057	0.491 ± 0.015	0.494 ± 0.009	0.415 ± 0.009	0.266 ± 0.011Roc(i)	1	0.737 ± 0.081	0.742 ± 0.089	0.764 ± 0.067	0.799 ± 0.007	0.791 ± 0.004	0.708 ± 0.008	0.499 ± 0.013	2	0.709 ± 0.070	0.713 ± 0.077	0.733 ± 0.058	0.765 ± 0.009	0.760 ± 0.008	0.694 ± 0.007	0.502 ± 0.014	3	0.697 ± 0.065	0.701 ± 0.071	0.719 ± 0.054	0.750 ± 0.008	0.746 ± 0.008	0.690 ± 0.006	0.500 ± 0.014	4	0.696 ± 0.063	0.699 ± 0.068	0.715 ± 0.053	0.744 ± 0.005	0.741 ± 0.006	0.690 ± 0.007	0.501 ± 0.015Roc(c)	1	0.741 ± 0.088	0.747 ± 0.092	0.775 ± 0.075	0.821 ± 0.011	0.819 ± 0.006	0.725 ± 0.014	0.493 ± 0.034	2	0.707 ± 0.072	0.712 ± 0.076	0.735 ± 0.061	0.774 ± 0.009	0.774 ± 0.007	0.704 ± 0.012	0.496 ± 0.027	3	0.686 ± 0.061	0.691 ± 0.067	0.711 ± 0.052	0.746 ± 0.007	0.745 ± 0.003	0.690 ± 0.011	0.497 ± 0.028	4	0.667 ± 0.056	0.672 ± 0.059	0.689 ± 0.048	0.722 ± 0.007	0.721 ± 0.005	0.675 ± 0.014	0.497 ± 0.025The λ coefficient controls the strength of prior—i.e. the tradeoff between the prediction and reconstruction loss.
Table 30: Summary λ-Sensitivities for TEA on linear model with UKCF (Bold indicates best)I λ = 0	λ = 0.01	λ = 0.1	λ = 0.5	λ=0.9	λ = 0.99	λ=1PRC(I) 10.347 ± 0.085	0.357 ± 0.090	0.381 ± 0.078	0.431 ± 0.031	0.424 ± 0.027	0.318 ± 0.013	0.162 ± 0.011PRC(C)10.433 ± 0.083	0.443 ± 0.087	0.477 ± 0.084	0.543 ± 0.054	0.546 ± 0.050	0.424 ± 0.012	0.252 ± 0.016ROC(I) 10.710 ± 0.072	0.714 ± 0.078	0.733 ± 0.061	0.764 ± 0.022	0.759 ± 0.020	0.695 ± 0.010	0.501 ± 0.014ROC(C) 10.700 ± 0.075	0.705 ± 0.080	0.727 ± 0.068	0.766 ± 0.038	0.765 ± 0.037	0.698 ± 0.022	0.496 ± 0.029The λ coefficient controls the strength of prior—i.e. the tradeoff between the prediction and reconstruction loss.
Table 31: Extended N -Sensitivities for REG on linear model with UKCF (Bold indicates best)	T	N × 1%	N × 5%	N × 20%	N × 50%	N × 100%	 Prc(i)	1	0.160 ± 0.010	0.176±0.024	0.199 ± 0.044	0.325 ± 0.114	0.370 ± 0.101	2	0.172 ± 0.009	0.187 ±0.021	0.207 ± 0.037	0.312 ± 0.095	0.350 ± 0.085	3	0.180 ± 0.011	0.192±0.020	0.209 ± 0.032	0.303 ± 0.085	0.337 ± 0.076	4	0.182 ± 0.009	0.193±0.020	0.208 ± 0.028	0.295 ± 0.078	0.328 ± 0.071Prc(c)	1	0.246 ± 0.011	0.268 ± 0.034	0.293 ± 0.046	0.421 ± 0.119	0.467 ± 0.106	2	0.263 ± 0.011	0.283 ± 0.027	0.304 ± 0.036	0.401 ± 0.091	0.435 ± 0.081	3	0.275 ± 0.013	0.292 ± 0.028	0.313±0.032	0.390 ± 0.076	0.418 ± 0.067	4	0.286 ± 0.013	0.302 ± 0.025	0.319 ±0.029	0.384 ± 0.066	0.412 ± 0.060Roc(i)	τ	0.512 ± 0.024	0.553 ± 0.046	0.598 ± 0.057	0.705 ± 0.090	0.737 ± 0.081	2	0.516 ± 0.025	0.557 ± 0.040	0.594 ± 0.049	0.681 ± 0.077	0.709 ± 0.07031Published as a conference paper at ICLR 2020	3	0.521 ± 0.026	0.549 ± 0.037	0.590 ± 0.045	0.671 ± 0.071	0.697 ± 0.065	4	0.519 ± 0.024	0.546 ± 0.037	0.590 ± 0.039	0.669 ± 0.068	0.696 ± 0.063	 Roc(c)	1	0.507 ± 0.026	0.539 ± 0.049	0.591 ± 0.054	0.702 ± 0.101	0.741 ± 0.088	2	0.520 ± 0.024	0.546 ± 0.040	0.587 ± 0.041	0.675 ± 0.082	0.707 ± 0.072	3	0.526 ± 0.023	0.549 ± 0.038	0.586 ± 0.036	0.659 ± 0.070	0.686 ± 0.061	4	0.528 ± 0.027	0.550 ± 0.039	0.581 ± 0.034	0.642 ± 0.062	0.667 ± 0.056
Table 32: Summary N -Sensitivities for REG on linear model with UKCF (Bold indicates best)	I	N × 1%	N × 5%	N × 20%	N × 50%	N × 100%Prc(i)	I 0.173 ± 0.013	0.187 ± 0.022	0.206 ± 0.036	0.309 ± 0.094	0.347 ± 0.085Prc(c)	I 0.267 ± 0.019	0.286 ± 0.031	0.307 ± 0.038	0.399 ± 0.092	0.433 ± 0.083Roc(i)	I 0.517 ± 0.025	0.551 ± 0.041	0.593 ± 0.048	0.682 ± 0.078	0.710 ± 0.072Roc(c)	I 0.520 ± 0.026	0.546 ± 0.042	0.586 ± 0.042	0.669 ± 0.083	0.700 ± 0.075The proportion of data N used is randomly restricted, showing performance under various levels of data scarcity.
Table 33: Extended N -Sensitivities for TEA on linear model with UKCF (Bold indicates best)	T	N × 1%	N × 5%	N × 20%	N × 50%	N × 100%	 Prc(i)	1	0.199 ± 0.016	0.342 ± 0.040	0.453 ± 0.020	0.486 ± 0.017	0.497 ± 0.016	2	0.205 ± 0.013	0.336 ± 0.031	0.421 ± 0.017	0.448 ± 0.015	0.459 ± 0.017	3	0.212 ± 0.018	0.322±0.027	0.398 ± 0.015	0.420 ± 0.014	0.432 ± 0.015	4	0.210 ± 0.016	0.308 ± 0.025	0.381 ± 0.011	0.402 ± 0.011	0.413 ± 0.010Prc(c)	1	0.287 ± 0.021	0.470 ± 0.060	0.610 ± 0.017	0.642 ± 0.012	0.653 ± 0.009	2	0.292 ± 0.018	0.445 ± 0.041	0.535 ± 0.014	0.557 ± 0.012	0.566 ± 0.010	3	0.302 ± 0.014	0.424 ± 0.034	0.495 ± 0.011	0.514 ± 0.009	0.521 ± 0.008	4	0.311 ± 0.017	0.417±0.030	0.478 ± 0.014	0.493 ± 0.010	0.498 ± 0.009Roc(i)	1	0.570 ± 0.022	0.698 ± 0.027	0.776 ± 0.008	0.797 ± 0.007	0.806 ± 0.007	2	0.565 ± 0.027	0.684±0.019	0.744 ± 0.010	0.763 ± 0.007	0.771 ± 0.007	3	0.568 ± 0.027	0.663 ± 0.021	0.723 ± 0.011	0.740 ± 0.009	0.750 ± 0.007	4	0.564 ± 0.026	0.652±0.020	0.707 ± 0.010	0.729 ± 0.010	0.740 ± 0.008Roc(c)	1	0.581 ± 0.017	0.715±0.032	0.795 ± 0.009	0.822 ± 0.007	0.829 ± 0.006	2	0.565 ± 0.015	0.684±0.019	0.745 ± 0.006	0.768 ± 0.007	0.775 ± 0.008	3	0.570 ± 0.015	0.668 ± 0.018	0.718±0.007	0.737 ± 0.005	0.743 ± 0.005	4	0.570 ± 0.020	0.653 ± 0.015	0.698 ± 0.008	0.715 ± 0.008	0.720 ± 0.006The proportion of data N used is randomly restricted, showing performance under various levels of data scarcity.
Table 34: Summary N -Sensitivities for TEA on linear model with UKCF (Bold indicates best)	I	N × 1%	N × 5%	N × 20%	N × 50%	N × 100%Prc(i)	I 0.207 ± 0.017	0.327 ± 0.034	0.413 ± 0.031	0.439 ± 0.035	0.450 ± 0.035Prc(c)	I 0.298 ± 0.020	0.439 ± 0.047	0.530 ± 0.053	0.551 ± 0.058	0.559 ± 0.060Roc(i)	I 0.567 ± 0.026	0.674 ± 0.029	0.738 ± 0.027	0.757 ± 0.027	0.767 ± 0.026Roc(c)	I 0.572 ± 0.018	0.680 ± 0.032	0.739 ± 0.038	0.760 ± 0.041	0.767 ± 0.042The proportion of data N used is randomly restricted, showing performance under various levels of data scarcity.
Table 35: Results for Tea and comparators on linear model for negative example (Bold indicates best)	I	Base	Reg	Fea	Tea	F/TeaMse	I 0.266 ± 0.045	0.266 ± 0.045	0.266 ± 0.045	0.285 ± 0.047	0.280 ± 0.045Mse(u)	I 0.333 ± 0.056	0.333 ± 0.056	0.333 ± 0.056	0.334 ± 0.056	0.334 ± 0.056Mse(p)	I 0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.087 ± 0.028	0.061 ± 0.022Mse metrics are further reported separately for targets that are in principle predictable (P) and unpredictable (U).
Table 36: λ-Sensitivities for TEA on linear model for negative example (Bold indicates best)	I	λ = 0	λ = 0.01	λ = 0.1	λ = 0.5	λ= 0.9Mse	I 0.266 ± 0.045	0.267 ± 0.045	0.271 ± 0.046	0.285 ± 0.047	0.292 ± 0.051Mse(u)	I 0.333 ± 0.056	0.333 ± 0.056	0.334 ± 0.056	0.334±0.056	0.334 ± 0.056Mse(p)	I 0.000 ± 0.000	0.003 ± 0.005	0.022 ± 0.009	0.087 ± 0.028	0.125 ± 0.063Mse metrics are further reported separately for targets that are in principle predictable (P) and unpredictable (U).
Table 37: Performance degradation for Tea and comparators on linear model with UKCF (Bold indicates best)	Base	REG	FEA	Tea	F/TEA	 Roc(i)	0.019 ± 0.015	0.020 ± 0.014	0.019 ± 0.015	0.020 ± 0.016	0.017 ± 0.014Roc(c)	0.025 ± 0.015	0.029 ± 0.015	0.024±0.014	0.013 ± 0.020	0.019 ± 0.018Prc(i)	0.022 ± 0.020	0.018 ± 0.021	0.021 ± 0.022	0.033 ± 0.022	0.027 ± 0.022Prc(c)	0.026 ± 0.021	0.029 ± 0.018	0.026 ± 0.019	0.018 ± 0.023	0.021 ± 0.019Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
Table 38: Performance by training stages for Tea on linear model with UKCF (Bold indicates best); columnheaders indicate the sequence of training stages executed (note that “1-2-3” simply corresponds to Algorithm 1)	None	1-2	3	1-2-3	3-1-2	 Roc(i)	0.710 ± 0.072	0.747 ± 0.022	0.764 ± 0.022	0.767 ± 0.026	0.749 ± 0.022Roc(c)	0.700 ± 0.075	0.744 ± 0.038	0.766 ± 0.038	0.767 ± 0.042	0.747 ± 0.037Prc(i)	0.347 ± 0.085	0.402 ± 0.026	0.431 ± 0.031	0.450 ± 0.035	0.404 ± 0.027Prc(c)	0.433 ± 0.083	0.507 ± 0.040	0.543 ± 0.054	0.559 ± 0.060	0.512 ± 0.042Prc and Roc evaluations are reported separately for targets representing infections (I) and comorbidities (C).
